Inclusion Criteria:

1. Patients must have a diagnosis of the following autoimmune cytopenias:

immune thromobocytopenia purpura (ITP) autoimmune hemolytic anemia (AIHA) autoimmune
neutropenia (AIN) pure red cell aplasia (PRCA) and

2. Patients must have refractory disease according to the following criteria

1. not respond to steroids or

2. need prednisolone more than 15 mg/d for maintenance therapy

3. Complete work up for baseline evaluation and measurement

4. Age > 18 years

5. Patient's free written inform consent

Exclusion Criteria:

1. Patients with a known hypersensitivity to murine proteins or to any component of
alemtuzumab

2. Patients with poor performance status (ECOG criteria of 3-4)

3. Serologic evidence of human immunodeficiency virus exposure

4. Patients with active uncontrolled infection. Patients that are HIV positive or test
positive on HBs or HCV antigens.

5. Pregnant or lactating women

6. Serious medical or psychiatric illness which prevent informed consent

7. Patients who are likely to lost to follow up (eg, unwilling or difficult to return,
cannot be contacted)

8. Patients with active malignancies